Adipose tissue dysfunction is a key mechanism that leads to adiposity-based chronic disease. This study aimed to investigate the feasibility of the adiponectin/leptin ratio (AdipoQ/Lep) as an adipose tissue and metabolic function biomarker in adults with obesity, without diabetes. Data were collected from a clinical trial conducted in 28 adults with obesity (mean body mass index: 35.4±3.7 kg/m<sup>2</sup>) (NCT02169778). Using a forward stepwise multiple linear regression model to explore the relationship between AdipoQ/Lep and HOMA-IR, it was observed that 48.6% of HOMA-IR variance was explained by triacylglycerols, AdipoQ/Lep and waist-to-hip ratio (P&lt;0.001), being AdipoQ/Lep the strongest independent predictor (Beta = -0.449, P&lt;0.001). A lower AdipoQ/Lep was correlated with a higher body mass index (R<sub>s</sub> = -0.490, P&lt;0.001), body fat mass (R<sub>s</sub> = -0.486, P&lt;0.001), waist-to-height ratio (R<sub>S</sub> = -0.290, P=0.037), and plasma resistin (R<sub>s</sub> = -0.365, P=0.009). These data highlight the central role of adipocyte dysfunction in the pathogenesis of insulin resistance and emphasize that AdipoQ/Lep may be a promising early marker of insulin resistance development in adults with obesity.

Original languageEnglish
Pages (from-to)E115 - E119
JournalAmerican journal of physiology. Endocrinology and metabolism
Issue number2
Early online date9 Nov 2022
Publication statusPublished - 1 Feb 2023


  • adiponectin/leptin
  • adipose tissue dysfunction
  • insulin resistance
  • metabolic dysfunction
  • obesity


Dive into the research topics of 'Decreased adiponectin/leptin ratio relates to insulin resistance in adults with obesity'. Together they form a unique fingerprint.

Cite this